Taiga Biotechnologies IPO

Taiga Biotechnologies is a cell-based immunotherapy company focused on harnessing the power of the immune system to fight solid tumors and infectious disease.

Register for Details

For more details on financing and valuation for Taiga Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Taiga Biotechnologies

Forge green plus iconForge green minus icon

What is Taiga Biotechnologies's funding to date?

Taiga Biotechnologies has raised $42.83MM to date.
Forge green plus iconForge green minus icon

When was Taiga Biotechnologies founded?

Taiga Biotechnologies was founded in 2006.

Taiga Biotechnologies Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
5/31/2019 Series C $27.2MM raised $XXX.XX $XXX.XX
3/16/2017 Series B-1 $12MM raised $XXX.XX $XXX.XX
5/15/2014 Series B $3.17MM raised $XXX.XX $XXX.XX
5/30/2012 Series A $466.22K raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.